Top 5 Stocks to Buy Now
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free CRTX Stock Alerts

CRISM Therapeutics (CRTX) Competitors

GBX 9.50 -0.75 (-7.32%)
As of 08:19 AM Eastern
Compare

CRTX vs. GSP, ARCM, MET1, GWMO, and FCM

Should you buy CRISM Therapeutics stock or one of its competitors? MarketBeat compares CRISM Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CRISM Therapeutics include Gensource Potash (GSP), Arc Minerals (ARCM), Metals One (MET1), Great Western Mining (GWMO), and First Class Metals (FCM). These companies are all part of the "other industrial metals & mining" industry.

How does CRISM Therapeutics compare to Gensource Potash?

CRISM Therapeutics (LON:CRTX) and Gensource Potash (LON:GSP) are both small-cap basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled Gensource Potash'saverage media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Gensource Potash Neutral

CRISM Therapeutics has higher revenue and earnings than Gensource Potash. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Gensource Potash, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£25K206.09-£792.20K-£4.40N/A
Gensource PotashN/AN/A-£6.58M-£0.01N/A

3.7% of CRISM Therapeutics shares are owned by institutional investors. 73.8% of CRISM Therapeutics shares are owned by company insiders. Comparatively, 6.2% of Gensource Potash shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Gensource Potash's return on equity of -45.96% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -109.55% -26.77%
Gensource Potash N/A -45.96%-10.31%

CRISM Therapeutics has a beta of 0.585, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Gensource Potash has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

Summary

CRISM Therapeutics beats Gensource Potash on 5 of the 9 factors compared between the two stocks.

How does CRISM Therapeutics compare to Arc Minerals?

Arc Minerals (LON:ARCM) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Arc Minerals' return on equity of -28.44% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Arc MineralsN/A -28.44% -5.85%
CRISM Therapeutics N/A -109.55%-26.77%

3.2% of Arc Minerals shares are owned by institutional investors. Comparatively, 3.7% of CRISM Therapeutics shares are owned by institutional investors. 16.2% of Arc Minerals shares are owned by company insiders. Comparatively, 73.8% of CRISM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Arc Minerals has a beta of 0.13, indicating that its stock price is 87% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.585, indicating that its stock price is 42% less volatile than the broader market.

In the previous week, Arc Minerals' average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Arc Minerals Neutral
CRISM Therapeutics Neutral

Arc Minerals has higher earnings, but lower revenue than CRISM Therapeutics. Arc Minerals is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arc MineralsN/AN/A£9.42M-£0.25N/A
CRISM Therapeutics£25K206.09-£792.20K-£4.40N/A

Summary

CRISM Therapeutics beats Arc Minerals on 5 of the 9 factors compared between the two stocks.

How does CRISM Therapeutics compare to Metals One?

Metals One (LON:MET1) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Metals One's return on equity of -2.94% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Metals OneN/A -2.94% -112.94%
CRISM Therapeutics N/A -109.55%-26.77%

In the previous week, Metals One had 2 more articles in the media than CRISM Therapeutics. MarketBeat recorded 2 mentions for Metals One and 0 mentions for CRISM Therapeutics. Metals One's average media sentiment score of 0.31 beat CRISM Therapeutics' score of 0.00 indicating that Metals One is being referred to more favorably in the media.

Company Overall Sentiment
Metals One Neutral
CRISM Therapeutics Neutral

1.3% of Metals One shares are owned by institutional investors. Comparatively, 3.7% of CRISM Therapeutics shares are owned by institutional investors. 1.5% of Metals One shares are owned by insiders. Comparatively, 73.8% of CRISM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Metals One has higher earnings, but lower revenue than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Metals One, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Metals OneN/AN/A-£375.04K-£4.97N/A
CRISM Therapeutics£25K206.09-£792.20K-£4.40N/A

Summary

Metals One and CRISM Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Great Western Mining?

CRISM Therapeutics (LON:CRTX) and Great Western Mining (LON:GWMO) are both small-cap basic materials companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Great Western Mining's return on equity of -9.48% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -109.55% -26.77%
Great Western Mining N/A -9.48%-5.92%

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled Great Western Mining'saverage media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Great Western Mining Neutral

3.7% of CRISM Therapeutics shares are owned by institutional investors. Comparatively, 5.8% of Great Western Mining shares are owned by institutional investors. 73.8% of CRISM Therapeutics shares are owned by insiders. Comparatively, 6.3% of Great Western Mining shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CRISM Therapeutics has a beta of 0.585, meaning that its share price is 42% less volatile than the broader market. Comparatively, Great Western Mining has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Great Western Mining has lower revenue, but higher earnings than CRISM Therapeutics. Great Western Mining is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£25K206.09-£792.20K-£4.40N/A
Great Western MiningN/AN/AN/A-£0.01N/A

Summary

CRISM Therapeutics and Great Western Mining tied by winning 4 of the 8 factors compared between the two stocks.

How does CRISM Therapeutics compare to First Class Metals?

First Class Metals (LON:FCM) and CRISM Therapeutics (LON:CRTX) are both small-cap basic materials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

First Class Metals' return on equity of -55.27% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
First Class MetalsN/A -55.27% N/A
CRISM Therapeutics N/A -109.55%-26.77%

First Class Metals has a beta of 0.01640514, meaning that its share price is 98% less volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.585, meaning that its share price is 42% less volatile than the broader market.

In the previous week, First Class Metals' average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
First Class Metals Neutral
CRISM Therapeutics Neutral

CRISM Therapeutics has higher revenue and earnings than First Class Metals. First Class Metals is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
First Class MetalsN/AN/A-£2.20M-£0.61N/A
CRISM Therapeutics£25K206.09-£792.20K-£4.40N/A

5.6% of First Class Metals shares are owned by institutional investors. Comparatively, 3.7% of CRISM Therapeutics shares are owned by institutional investors. 5.7% of First Class Metals shares are owned by company insiders. Comparatively, 73.8% of CRISM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

CRISM Therapeutics beats First Class Metals on 5 of the 9 factors compared between the two stocks.

Get CRISM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRTX vs. The Competition

Export
MetricCRISM TherapeuticsOther Industrial Metals & Mining IndustryMaterials SectorLON Exchange
Market Cap£5.15M£1.49B£4.59B£2.77B
Dividend YieldN/A6.55%5.00%6.16%
P/E Ratio-2.1627.0622.60366.61
Price / Sales206.0944,965.815,473.8786,103.14
Price / CashN/A24.6327.0527.87
Price / Book0.225.258.717.85
Net Income-£792.20K£70.60M£157.26M£5.89B
7 Day Performance-5.00%-5.20%-4.58%-0.97%
1 Month Performance-20.10%-7.03%-5.61%-0.79%
1 Year Performance-52.74%85.07%48.81%68.88%

CRISM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
CRISM Therapeutics
N/AGBX 9.50
-7.3%		N/A-53.6%£5.15M£25KN/A4
GSP
Gensource Potash
N/AN/AN/AN/A£23.61MN/AN/AN/A
ARCM
Arc Minerals
N/AGBX 0.72
+5.9%		N/A-29.2%£17.59MN/AN/A35
MET1
Metals One
N/AGBX 1.50
-0.1%		N/A-91.9%£16.94MN/AN/A3
GWMO
Great Western Mining
N/AGBX 3.50
-4.1%		N/A+253.6%£15.16MN/AN/A9

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CRTX) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners
Kevin O'Leary Saw AI's Biggest Bottleneck Coming
Kevin O'Leary calls it the picks-and-shovels play for both Bitcoin and AI - and he put money behind it. While ...
The Tomorrow Investor | Sponsoredtc pixel
The Treasury just bought its own debt
On April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...
Golden Portfolio | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
BLOODBATH: 80% Dow Drop Predicted – Former Pentagon Advisor
A former advisor to the Pentagon and CIA is warning that an 80% Dow drop could arrive within days - and names ...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...
Porter & Company | Sponsoredtc pixel